Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 5;50(W1):W138-W144.
doi: 10.1093/nar/gkac384.

Cancer driver drug interaction explorer

Affiliations

Cancer driver drug interaction explorer

Michael Hartung et al. Nucleic Acids Res. .

Abstract

Cancer is a heterogeneous disease characterized by unregulated cell growth and promoted by mutations in cancer driver genes some of which encode suitable drug targets. Since the distinct set of cancer driver genes can vary between and within cancer types, evidence-based selection of drugs is crucial for targeted therapy following the precision medicine paradigm. However, many putative cancer driver genes can not be targeted directly, suggesting an indirect approach that considers alternative functionally related targets in the gene interaction network. Once potential drug targets have been identified, it is essential to consider all available drugs. Since tools that offer support for systematic discovery of drug repurposing candidates in oncology are lacking, we developed CADDIE, a web application integrating six human gene-gene and four drug-gene interaction databases, information regarding cancer driver genes, cancer-type specific mutation frequencies, gene expression information, genetically related diseases, and anticancer drugs. CADDIE offers access to various network algorithms for identifying drug targets and drug repurposing candidates. It guides users from the selection of seed genes to the identification of therapeutic targets or drug candidates, making network medicine algorithms accessible for clinical research. CADDIE is available at https://exbio.wzw.tum.de/caddie/ and programmatically via a python package at https://pypi.org/project/caddiepy/.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
CADDIE: prioritize drug targets and identify drug repurposing candidates with network medicine algorithms in cancer.
Figure 1.
Figure 1.
Seed genes for drug target and drug search can be selected from integrated cancer driver databases, via mutation or expression data from TCGA and GTEx using user-defined thresholds, or by uploading a list of genes (1). Based on the seed genes, putative drugs or drug target candidates are identified using a broad selection of network medicine algorithms that traverse the human gene-drug interactome (2). While the drug search reports drugs in proximity to the seed genes, the drug target search returns genes interacting with the disease module spanned by the seed genes (3).
Figure 2.
Figure 2.
Drug network computed with TrustRank for sarcoma with BioGRID gene–gene and drug–gene interactions. The cancer driver gene information is taken from COSMIC.

References

    1. Meacham C.E., Morrison S.J.. Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501:328–337. - PMC - PubMed
    1. Nogales C., Mamdouh Z.M., List M., Kiel C., Casas A.I., Schmidt H.H.. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol. Sci. 2022; 43:136–150. - PubMed
    1. Zhang Z., Zhou L., Xie N., Nice E.C., Zhang T., Cui Y., Huang C.. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct. Targeted Ther. 2020; 5:113. - PMC - PubMed
    1. Verma M. Personalized Medicine and Cancer. J. Pers, Med. 2012; 2:1–14. - PMC - PubMed
    1. Rubin E.H., Gilliland D.G.. Drug development and clinical trials—the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 2012; 9:215–222. - PubMed

Publication types

Substances